Antagonists of the kappa opioid receptor
US10118896B2 · kind B2 · utility
2Cited by
1References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 25, 2015 |
| Grant date | Nov 6, 2018 |
| Priority date | — |
| Expiry date | Dec 15, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D223/16
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.